[.
]
Action/Kinetics:
Peak serum levels: PO, 15-33 mcg/mL after 90 min.
t
1/2: PO, 78-96 min. 90% excreted unchanged in urine within 24 hr.
Uses:
UTIs caused by
Escherichia coli, Proteus mirabilis and
Klebsiella. Skin and skin structure infections due to staphylococci or streptococci. Pharyngitis and tonsillitis due to group A beta-hemolytic streptococci.
Special Concerns:
Safe use in children not established. C
CR determinations must be carried out in clients with renal impairment.
How Supplied:
Capsule: 500 mg;
Powder for Reconstitution: 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL;
Tablet: 1 g
Dosage
?Capsules, Oral Suspension, Tablets
Pharyngitis, tonsillitis.
Adults: 1 g/day in single or two divided doses for 10 days.
Children: 30 mg/kg/day in single or two divided doses (for beta-hemolytic streptococcoal infection, dose should be given for 10 or more days).
Skin and skin structure infections.
Adults: 1 g/day in single or two divided doses.
Children: 30 mg/kg/day in divided doses q 12 hr.
UTIs.
Adults: 1-2 g/day in single or two divided doses for uncomplicated lower UTI (e.g., cystitis). For all other UTIs, the usual dose is 2 g/day in two divided doses.
Children: 30 mg/kg/day in divided doses q 12 hr.
For clients with C
CR rates below 50 mL/min.
Initial: 1 g;
maintenance, 500 mg at following dosage intervals: q 36 hr for C
CR rates of 0-10 mL/min; q 24 hr for C
CR rates of 10-25 mL/min; q 12 hr for C
CR rates of 25-50 mL/min.
